Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment

Add time:08/15/2019    Source:sciencedirect.com

D3 receptors are prominently localized in the primate caudate–putamen, and D3 receptor agonist properties may offer an advantage in Parkinson’s disease therapy. In the present experiments, we investigated the relationship between D3 receptor mRNA, D3 receptor sites and the dopamine transporter in monkey basal ganglia by comparing their distribution in the brain of control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys (Samirai sciureus). In control monkeys, D3 receptor mRNA appears to be widely expressed throughout the brain, with a distribution similar to that observed in both man and rodent. D3 receptors are present in areas which express mRNA but also in some which do not, an observation which suggests they may be both pre- and postsynaptic in the monkey brain. Chronic MPTP administration, which selectively destroys the nigrostriatal system, resulted in a 70 to 99% depletion of the dopamine transporter in the basal ganglia. Autoradiographic analysis showed that after MPTP treatment there was a significant decline in D3 receptors in the caudate, but not putamen, globus pallidus, substantia nigra or other dopaminergic regions. D3 receptor mRNA expression was not changed in any region after nigrostriatal lesioning. Two weeks of l-3,4-dihydroxyphenylalanine (levodopa, l-DOPA) treatment, which alleviated Parkinsonism but also induced dyskinesias, reversed the MPTP-induced decline in caudate D3 receptors.These results show that there is a selective decline in D3 receptors in the caudate after nigrostriatal degeneration, which is reversed by l-DOPA treatment. Since the majority of dopaminergic nerve terminals were destroyed after MPTP lesioning, the reversal in D3 receptors after l-DOPA treatment may represent an increase in caudate postsynaptic receptors, which could conceivably contribute to an imbalance in striatal circuitry and the development of dyskinesias.

We also recommend Trading Suppliers and Manufacturers of levodopa isopropyl ester (cas 110301-07-0). Pls Click Website Link as below: cas 110301-07-0 suppliers

Prev:(6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease
Next:Pharmacokinetics of the Anticancer Agent Sulofenur (cas 110311-27-8) in Mice, Rats, Monkeys, and Dogs)